Literature DB >> 11315351

Apheresis for lupus erythematosus: state of the art.

D J Wallace1.   

Abstract

PP is a safe, expensive, labor-intensive procedure. Its absolute SLE indications include hyperviscosity, cryoglobulinemia, pulmonary hemorrhage and TTP. PP may be useful in cyclophosphamide-resistant, serious, organ-threatening disease. It may be potentially useful in the antiphospholipid syndrome or mothers or children at risk for congenital heart block. Refinements in apheresis technology may expand the indications for PP.

Entities:  

Mesh:

Year:  2001        PMID: 11315351     DOI: 10.1191/096120301671920760

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

Review 1.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

2.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

3.  Retrospective study of plasma exchange in children with systemic lupus erythematosus.

Authors:  Elizabeth C Wright; Kjell Tullus; Michael J Dillon
Journal:  Pediatr Nephrol       Date:  2004-08-05       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.